Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 1Phase 1/2 1

Status

Active not recruiting 3Completed 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Urinary Bladder Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

Carboplatin 314Paclitaxel 302Cisplatin 250Docetaxel 237pembrolizumab 230Gemcitabine 213Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 120Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 92Prednisone 91Oxaliplatin 89atezolizumab 73Leucovorin 71durvalumab 69130-nm albumin-bound paclitaxel 67Injections 64Lenalidomide 63Irinotecan 60Bortezomib 55Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Cystectomy × Clear all
NCT04960709 2026-04-14

VOLGA

AstraZeneca

Phase 3 Active not recruiting
712 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03924856 2025-08-28

KEYNOTE-866

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
907 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT03924895 2025-08-28

KEYNOTE-905

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
595 enrolled 1 FDA
Genitourinary

Urinary Bladder Neoplasms

NCT04209114 2024-06-27

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Bristol-Myers Squibb

Phase 3 Completed
114 enrolled 17 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡